France has one of the world’s finest medical care systems and is actively moving towards adopting the latest treatment methods, including the photon therapy.
The photon therapy is defined as a type of radiation treatment that utilizes photons and has some advantages over conventional (x-ray) radiation treatment. For example, one of them is the opportunity to direct and deposit the energy distribution in tissue volumes, which provides greater control and precision, and therefore, a better quality of life for the patient and a more advanced management of the disorder.
Thanks to the ability to energize photons to specific velocities to avoid unnecessary damage to healthy tissues while increasing the dose to the tumor, the photon therapy continues to attract the attention of cancer researchers and patients. For example, in addition to an advanced treatment opportunity, patients are interested in the potential for fewer side effects such as nausea, diarrhea, and vomiting. The reduction of these effects by proton therapy results in a better quality of life during and after treatment.
Why France? The country represents a huge untapped opportunity for this sophisticated treatment, according to a number of research publications. For example, a recent report published by iGATE research suggested that France photon therapy market will exceed $1.5 billion by 2021. This increase represents almost a double of the current market size.
Currently, France is planning a rapid increase in their proton beam therapy provision in the next several years together with other European countries. Specifically, the existing cancer hospitals in France are getting major upgrades while the government is planning the opening of new ones. It is clear that the commitment to maintain the second-largest proton therapy market share is high, and it makes the country one of the best options for quality treatment.
Every proton therapy center in France offers a wide range of solutions for patients delivered by cutting-edge equipment. For example, the latest in proton therapy technology including Modulated Proton Therapy (MPT), Cone-Beam CT (CBCT), and proton accelerators are available. The recent addition of Proteus®ONE, a compact proton therapy system will only increase the access to the treatment.
Clearly, the proton therapy in France is a fast-evolving, high-growth market which will remain at the leading position in Europe. With the current level of support and innovation, it is sufficient to claim that the country provides quality treatment for cancer patients in state-of-the-art centers.